Loading...
  • diagnosis
  • The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. (uptodate.com)
  • ammonia
  • Current treatment strategies include measures aimed at reducing the serum level of ammonia, providing specialized nursing care as well as correcting precipitating factors such as gastrointestinal hemorrhage, infection, constipation, and electrolyte disturbances [ 5 ]. (hindawi.com)
  • Current treatment strategies are directed at reducing ammonia, with newer agents showing some early promise. (hindawi.com)
  • The neurological abnormalities associated with this condition are attributed to elevated levels of circulating ammonia, mercaptans, aromatic amino acids Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.efficacy in hepatic encephalopathy. (uzbpmany.ml)
  • cytochrome
  • Those with RAR activity decreased hepatic cytochrome P450 (CYP or P450) levels and in vitro metabolism of the compound of pretreatment, whereas those exerting predominantly RXR activity increased these parameters. (aspetjournals.org)
  • dysfunction
  • Defitelio (defibrotide sodium) is an injectable drug developed by Jazz Pharmaceuticals, for the treatment of hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome, in adults and children with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). (drugdevelopment-technology.com)
  • The US FDA's approval of Defitelio (defibrotide sodium) was based on the results obtained from three clinical studies (phase 2, phase 3 and expanded access studies) conducted on patients with Hepatic VOD with renal or pulmonary dysfunction. (drugdevelopment-technology.com)
  • This compassionate use study will include patients with advanced cancer requiring PN for long-term nutrition support who have developed PN-induced hepatic injury or who have existing hepatic dysfunction. (knowcancer.com)
  • chemotherapy
  • Recent data suggest that rituximab-based chemotherapy induces an increase in HCV expression in hepatic cells, which may become a target for a cell-mediated immune reaction after the withdrawal of treatment and the restoration of the immune control. (hindawi.com)
  • However, the noninvasive treatments (vaccinotherapy, immunotherapy, chemotherapy) used so far did not lead to a cure. (medicinamoderna.ro)
  • The results of chemotherapy as a single treatment are 10-13% cure, 40-60% partial remission, 10-30% failure (1,2). (medicinamoderna.ro)
  • abnormalities
  • HE occurs in the presence of insufficient hepatic clearance of toxins absorbed from the intestine resulting in neurochemical abnormalities across the blood brain barrier [ 3 ]. (hindawi.com)
  • It manifests itself as a neuropsychiatric syndrome which may result in impairment of the sleep-wake cycle, cognition, memory, consciousness, personality changes, motor-sensory abnormalities, and decreased energy levels representing a continuum of manifestations of hepatic encephalopathy that can be experienced by the patient or elicited by the physician on history taking or physical examination [ 17 ]. (hindawi.com)
  • Hepatic encephalopathy (HE) is characterised by a complex of neurological abnormalities that occur due to congenital or acquired abnormalities in hepatic structure or function. (uzbpmany.ml)
  • Insufficient insulin replacement, decreased portal insulin-to-glucagon ratios and/or hyperglycemia-induced insulin resistance may account for the abnormalities of hepatic glucose metabolism in type 1 diabetes. (diabetesjournals.org)
  • Surgery
  • Hospitalization is limited to the time when surgery is planned as a treatment option. (medscape.com)
  • Experimental models of hepatic CS are reproduced mainly in rats, the most often by surgery methods. (msk.ru)
  • percutaneous
  • Abscesses should be treated at the time of identification, but percutaneous drainage and antibiotics are usually adequate treatment. (medscape.com)
  • Antihydatid agents are used in conjunction with percutaneous treatment. (medscape.com)
  • Medical therapy should be started 4 days before percutaneous treatment and continued either for 1 month (albendazole) or for 3 months (mebendazole), according to the World Health Organization (WHO) recommendations. (medscape.com)
  • This percutaneous treatment with sclerosing agents was introduced in the 1980s. (medscape.com)
  • toxins
  • Treatment is, therefore, based on mechanisms to reduce the production and absorption of gut-derived toxins such as decreasing and modifying dietary protein intake, altering the intestinal bacterial flora and bowel cleansing, and on mechanisms designed to modify central neurotransmitter balance either directly by use of dopaminergic agents or benzodiazepine antagonists or indirectly by use of amino-acid mixtures. (mysciencework.com)
  • P450
  • Testosterone replacement treatments carried out for 2 weeks slightly but significantly affected the suppression of P450 IIC11 and reversed the changes in P450 IIA2, IIIA2, and IIC12 in the diabetic male, without altering the suppressed state of growth hormone secretion. (aspetjournals.org)
  • However, 1 week of human growth hormone, administered intravenously every 4 hr to diabetic male rats, failed to significantly reverse the diabetes-induced changes in hepatic cytochromes P450, in particular forms IIC11 and IIE1, despite the presence of an episodic plasma hGH profile. (aspetjournals.org)
  • However, the lack of effect of human growth hormone treatment in the diabetic male on levels of individual P450 forms indicates that in diabetes there may be a change in the ability of the male rat hepatocyte to respond to a somatic signal, possibly as a result of the changes in other hormone factors. (aspetjournals.org)
  • therapy
  • No medical therapy has proved effective in reducing the size of simple hepatic cysts. (medscape.com)
  • Until relatively recently, no medical therapy capable of reducing the size of hepatic hemangiomas had been described. (medscape.com)
  • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program," Journal of Clinical Oncology , vol. 16, no. 8, pp. 2825-2833, 1998. (hindawi.com)
  • For obvious reasons, systemic treatment is the more appropriate therapy for patients with more extensive extrahepatic disease, if available. (springer.com)
  • Therapy with Omegaven will be provided at an initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. (knowcancer.com)
  • placebo
  • Patients were randomized on a 1:1 basis to receive 2.5 mg/kg of givosiran or placebo subcutaneously administered monthly, over a 6-month treatment period. (drugs.com)
  • metabolism
  • Although the mechanisms underlying these effects are not known, these results suggest that RAR- and RXR-binding ligands exert distinct effects on hepatic metabolism, and they indicate the potential for drug-drug interactions, especially involving CYP3A. (aspetjournals.org)
  • prevention
  • Hassab MA (1964) Gastroesophageal deconection and splenectomy: A method of prevention and treatment of bleeding from esophageal varices associated with bilharzial hepatic fibrosis. (springer.com)
  • 2018
  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 21, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias (AHPs). (drugs.com)
  • reduction
  • A case report in 2008 demonstrated reduction in the size of hepatic hemangiomas in a patient treated for colon cancer. (medscape.com)
  • In conclusion, poorly controlled type 1 diabetic patients present with marked reduction in both hepatic glycogen synthesis and breakdown. (diabetesjournals.org)
  • Poorly controlled type 1 diabetic patients exhibit impaired suppression of endogenous glucose production after a mixed meal ( 6 ) and reduction in hepatic glycogen accumulation, which becomes most prominent after dinner ( 7 ). (diabetesjournals.org)
  • Reduction in hepatic glycogen stores may therefore impair the rapid response of glucose production to hypoglycemia in type 1 diabetes. (diabetesjournals.org)